top of page
Systemic Therapeutics Logo

Systemic Therapeutics Announces the Appointment of Its Executive Team

Updated: Apr 22

Hamilton, Ontario--(Newsfile Corp. - January 31, 2022) - Systemic Therapeutics Corp. (the "Company" or "SystemicTx") is a pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulators of lipid metabolism, the sterol regulatory-element binding proteins (SREBP), based on first-in-class SREBP inhibitors. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as dyslipidemia and Non-Alcoholic Steatohepatitis (NASH).

SystemicTx is pleased to announce the appointment of its executive team, characterized by deep experience and proven track records of building and scaling businesses and drug developments across a variety of industries. The SystemicTx team includes physicians, scientists, geneticists, entrepreneurs, drug discovery and intellectual property experts.

"We are tremendously excited about this opportunity to bring together world class experts in human genetics, molecular and cellular biology and medicinal chemistry into one team with the sole purpose of developing the next generation of medicines for the treatment of cardiometabolic diseases and their vascular complications," commented Richard Austin, Co-Founder, Executive Chairman and Chief Scientific Officer.



bottom of page